Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price shot up 8.3% on Tuesday . The company traded as high as C$0.07 and last traded at C$0.07. Approximately 77,822 shares changed hands during trading, an increase of 63% from the average session volume of 47,821 shares. The stock had previously closed at C$0.06.
Hemostemix Stock Performance
The stock’s 50-day moving average price is C$0.06 and its 200-day moving average price is C$0.07. The company has a current ratio of 0.24, a quick ratio of 0.48 and a debt-to-equity ratio of -66.09. The company has a market capitalization of C$14.35 million, a P/E ratio of -3.50 and a beta of 0.21.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Further Reading
- Five stocks we like better than Hemostemix
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
